Publications

• Multicenter validation of automated detection of paramagnetic rim lesions on brain MRI in multiple sclerosis.Chen L, Ren Z, Clark KA, Lou C, Liu F, Cao Q, Manning AR, Martin ML, Luskin E, O'Donnell CM, Azevedo CJ, Calabresi PA, Freeman L, Henry RG, Longbrake EE, Oh J, Papinutto N, Bilello M, Song JW, Kaisey M, Sicotte NL, Reich DS, Solomon AJ, Ontaneda D, Sati P, Absinta M, Schindler MK, Shinohara RT. J Neuroimaging. 2024 Nov-Dec; 2024 Oct 15. PMID: 39410780.
• Multicenter automated central vein sign detection performs as well as manual assessment for the diagnosis of multiple sclerosis.Manning AR, Letchuman V, Martin ML, Gombos E, Roberts-Fitzgerald T, Cao Q, Raza P, O'Donnell CM, Renner B, Daboul L, Rodrigues P, Ramos M, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi PA, Cree BA, Freeman L, Henry RG, Longbrake EE, Oh J, Papinutto N, Pelletier D, Samudralwar RD, Suthiphosuwan S, Schindler MK, Bilello M, Song JW, Sotirchos ES, Sicotte NL, Al-Louzi O, Solomon AJ, Reich DS, Ontaneda D, Sati P, Shinohara RT. AJNR Am J Neuroradiol. 2024 Sep 27; 2024 Sep 27. PMID: 39332906.
• Diagnostic performance of central vein sign versus oligoclonal bands for multiple sclerosis.Toljan K, Daboul L, Raza P, Martin ML, Cao Q, O'Donnell CM, Rodrigues P, Derbyshire J, Azevedo CJ, Bar-Or A, Caverzasi E, Calabresi PA, Cree BA, Freeman L, Henry RG, Longbrake EE, Oh J, Papinutto N, Pelletier D, Samudralwar RD, Schindler MK, Sotirchos ES, Sicotte NL, Solomon AJ, Shinohara RT, Reich DS, Sati P, Ontaneda D. Mult Scler. 2024 Sep; 2024 Sep 5. PMID: 39234802.
• Gut Microbiome Wellness Index 2 enhances health status prediction from gut microbiome taxonomic profiles.Chang D, Gupta VK, Hur B, Cobo-López S, Cunningham KY, Han NS, Lee I, Kronzer VL, Teigen LM, Karnatovskaia LV, Longbrake EE, Davis JM 3rd, Nelson H, Sung J. Nat Commun. 2024 Aug 28; 2024 Aug 28. PMID: 39198444.
• Meta-analysis identifies common gut microbiota associated with multiple sclerosis.Lin Q, Dorsett Y, Mirza A, Tremlett H, Piccio L, Longbrake EE, Choileain SN, Hafler DA, Cox LM, Weiner HL, Yamamura T, Chen K, Wu Y, Zhou Y. Genome Med. 2024 Jul 31; 2024 Jul 31. PMID: 39085949.
• Choroid plexus volume differentiates MS from its mimics.Levit E, Ren Z, Gonzenbach V, Azevedo CJ, Calabresi PA, Cree BA, Freeman L, Longbrake EE, Oh J, Schindler MK, Sicotte NL, Reich DS, Ontaneda D, Sati P, Cao Q, Shinohara RT, Solomon AJ. Mult Scler. 2024 Jul; 2024 Mar 13. PMID: 38481081.
• Shifting our attention earlier in the multiple sclerosis disease course.Epstein SE, Longbrake EE. Curr Opin Neurol. 2024 Jun 1; 2024 Mar 28. PMID: 38546031.
• Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis.Cross AH, Gelfand JM, Thebault S, Bennett JL, von Büdingen HC, Cameron B, Carruthers R, Edwards K, Fallis R, Gerstein R, Giacomini PS, Greenberg B, Hafler DA, Ionete C, Kaunzner UW, Kodama L, Lock C, Longbrake EE, Musch B, Pardo G, Piehl F, Weber MS, Yuen S, Ziemssen T, Bose G, Freedman MS, Anania VG, Ramesh A, Winger RC, Jia X, Herman A, Harp C, Bar-Or A. JAMA Neurol. 2024 Mar 11; 2024 Mar 11. PMID: 38466277.
• A Noncanonical CD56dimCD16dim/- NK Cell Subset Indicative of Prior Cytotoxic Activity Is Elevated in Patients with Autoantibody-Mediated Neurologic Diseases.Yandamuri SS, Filipek B, Lele N, Cohen I, Bennett JL, Nowak RJ, Sotirchos ES, Longbrake EE, Mace EM, O'Connor KC. J Immunol. 2024 Mar 1. PMID: 38251887.
• Systems Analysis of Immune Changes after B-cell Depletion in Autoimmune Multiple Sclerosis.Wei J, Moon J, Yasumizu Y, Zhang L, Radassi K, Buitrago-Pocasangre N, Deerhake ME, Strauli N, Chan A, Herman A, Pedotte R, Raposo C, Tackenberg B, Yim I, Pappalardo J, Longbrake EE, Sumida TS, Axisa PP, Hafler DA. bioRxiv. 2024 Feb 9; 2024 Feb 9. PMID: 38370778.
• Impact of the COVID-19 Pandemic on the Personal Networks and Neurological Outcomes of People With Multiple Sclerosis: Cross-Sectional and Longitudinal Case-Control Study.Riley C, Venkatesh S, Dhand A, Doshi N, Kavak K, Levit E, Perrone C, Weinstock-Guttman B, Longbrake E, De Jager P, Xia Z. JMIR Public Health Surveill. 2024 Feb 6; 2024 Feb 6. PMID: 38319703.
• A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis.Daboul L, O'Donnell CM, Amin M, Rodrigues P, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi PA, Cree BA, Freeman L, Henry RG, Longbrake EE, Oh J, Papinutto N, Pelletier D, Prchkovska V, Raza P, Ramos M, Samudralwar RD, Schindler MK, Sotirchos ES, Sicotte NL, Solomon AJ, Shinohara RT, Reich DS, Sati P, Ontaneda D. Mult Scler. 2024 Jan; 2023 Dec 13. PMID: 38088067.
• Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management.Alvarez E, Longbrake EE, Rammohan KW, Stankiewicz J, Hersh CM. Mult Scler Relat Disord. 2023 Nov; 2023 Sep 15. PMID: 37783194.
• Anti-CD20 monoclonal antibody therapy in postpartum women with neurological conditions.Anderson A, Rowles W, Poole S, Balan A, Bevan C, Brandstadter R, Ciplea AI, Cooper J, Fabian M, Hale TW, Jacobs D, Kakara M, Krysko KM, Longbrake EE, Marcus J, Repovic P, Riley CS, Romeo AR, Rutatangwa A, West T, Hellwig K, LaHue SC, Bove R. Ann Clin Transl Neurol. 2023 Nov; 2023 Sep 7. PMID: 37675826.
• Gut Microbiome Wellness Index 2 for Enhanced Health Status Prediction from Gut Microbiome Taxonomic Profiles.Chang D, Gupta VK, Hur B, Cobo-López S, Cunningham KY, Han NS, Lee I, Kronzer VL, Teigen LM, Karnatovskaia LV, Longbrake EE, Davis JM 3rd, Nelson H, Sung J. bioRxiv. 2023 Oct 2; 2023 Oct 2. PMID: 37873265.
• Microfluidic Immuno-Serolomic Assay Reveals Systems Level Association with COVID-19 Pathology and Vaccine Protection.Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan JM, Buitrago-Pocasangre NC, Lele N, Asashima H, Racke MK, Wilson JE, Givens TS, Tomayko MM, Schulz WL, Longbrake EE, Hafler DA, Halene S, Fan R. Small Methods. 2023 Oct; 2023 Jun 13. PMID: 37312418.
• Early Treatment for Multiple Sclerosis: Time Is Brain.Longbrake EE, Kalincik T. Neurology. 2023 Sep 26; 2023 Jul 19. PMID: 37468283.
• Influence of menstrual cycle and hormonal contraceptive use on MS symptom fluctuations: A pilot study.Taylor H, Alhasan S, Saleem M, Poole S, Jiang F, Longbrake EE, Bove R. Mult Scler Relat Disord. 2023 Sep; 2023 Jun 30. PMID: 37480738.
• Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination.Asashima H, Kim D, Wang K, Lele N, Buitrago-Pocasangre NC, Lutz R, Cruz I, Raddassi K, Ruff WE, Racke MK, Wilson JE, Givens TS, Grifoni A, Weiskopf D, Sette A, Kleinstein SH, Montgomery RR, Shaw AC, Li F, Fan R, Hafler DA, Tomayko MM, Longbrake EE. JCI Insight. 2023 Aug 22; 2023 Aug 22. PMID: 37606046.
• MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity.Yandamuri SS, Filipek B, Obaid AH, Lele N, Thurman JM, Makhani N, Nowak RJ, Guo Y, Lucchinetti CF, Flanagan EP, Longbrake EE, O'Connor KC. JCI Insight. 2023 Jun 8; 2023 Jun 8. PMID: 37097758.
• Time for the Next Step in Clinical Trial Evolution?Longbrake EE. Ann Neurol. 2023 Jun; 2023 Apr 10. PMID: 36976460.
• Future of Neurology & Technology: Neuroimaging Made Accessible Using Low-Field, Portable MRI.Parasuram NR, Crawford AL, Mazurek MH, Chavva IR, Beekman R, Gilmore EJ, Petersen NH, Payabvash S, Sze G, Eugenio Iglesias J, Omay SB, Matouk C, Longbrake EE, de Havenon A, Schiff SJ, Rosen MS, Kimberly WT, Sheth KN. Neurology. 2023 May 30; 2023 Jan 31. PMID: 36720639.
• Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity.Shinoda K, Li R, Rezk A, Mexhitaj I, Patterson KR, Kakara M, Zuroff L, Bennett JL, von Büdingen HC, Carruthers R, Edwards KR, Fallis R, Giacomini PS, Greenberg BM, Hafler DA, Ionete C, Kaunzner UW, Lock CB, Longbrake EE, Pardo G, Piehl F, Weber MS, Ziemssen T, Jacobs D, Gelfand JM, Cross AH, Cameron B, Musch B, Winger RC, Jia X, Harp CT, Herman A, Bar-Or A. Proc Natl Acad Sci U S A. 2023 Jan 17; 2023 Jan 12. PMID: 36634138.
• Effect of GBCA Use on Detection and Diagnostic Performance of the Central Vein Sign: Evaluation Using a 3-T FLAIR* Sequence in Patients With Suspected Multiple Sclerosis.Daboul L, O'Donnell CM, Cao Q, Amin M, Rodrigues P, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi P, Cree BAC, Freeman L, Henry RG, Longbrake EE, Nakamura K, Oh J, Papinutto N, Pelletier D, Samudralwar RD, Suthiphosuwan S, Schindler MK, Sotirchos ES, Sicotte NL, Solomon AJ, Shinohara RT, Reich DS, Ontaneda D, Sati P. AJR Am J Roentgenol. 2023 Jan; 2022 Aug 17. PMID: 35975888.
• Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease.Peters J, Longbrake EE. Mult Scler Relat Disord. 2022 Dec; 2022 Nov 5. PMID: 36544307.
• High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.Freeman L, Longbrake EE, Coyle PK, Hendin B, Vollmer T. CNS Drugs. 2022 Dec; 2022 Nov 9. PMID: 36350491.
• Impact of resilience, social support, and personality traits in patients with neuroinflammatory diseases during the COVID-19 pandemic.Jakimovski D, Kavak KS, Longbrake EE, Levit E, Perrone CM, Bar-Or A, Benedict RH, Riley CS, De Jager PL, Venkatesh S, Walker ELS, Xia Z, Weinstock-Guttman B. Mult Scler Relat Disord. 2022 Dec; 2022 Oct 9. PMID: 36283322.
• The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome.Longbrake EE, Hua LH, Mowry EM, Gauthier SA, Alvarez E, Cross AH, Pei J, Priest J, Raposo C, Hafler DA, Winger RC. Mult Scler Relat Disord. 2022 Dec; 2022 Aug 22. PMID: 36031693.
• Impact of the COVID-19 Pandemic on Personal Networks and Neurological Outcomes of People with Multiple Sclerosis: A Case-Control Cross-sectional and Longitudinal Analysis.Riley CS, Venkatesh S, Dhand A, Doshi N, Kavak K, Levit EE, Perrone C, Weinstock-Guttman B, Longbrake EE, De Jager PL, Xia Z. medRxiv. 2022 Nov 29; 2022 Nov 29. PMID: 36203554.
• Toward Precision Phenotyping of Multiple Sclerosis.Pitt D, Lo CH, Gauthier SA, Hickman RA, Longbrake E, Airas LM, Mao-Draayer Y, Riley C, De Jager PL, Wesley S, Boster A, Topalli I, Bagnato F, Mansoor M, Stuve O, Kister I, Pelletier D, Stathopoulos P, Dutta R, Lincoln MR. Neurol Neuroimmunol Neuroinflamm. 2022 Nov; 2022 Aug 30. PMID: 36041861.
• Impaired TIGIT expression on B cells drives circulating follicular helper T cell expansion in multiple sclerosis.Asashima H, Axisa PP, Pham THG, Longbrake EE, Ruff WE, Lele N, Cohen I, Raddassi K, Sumida TS, Hafler DA. J Clin Invest. 2022 Oct 17; 2022 Oct 17. PMID: 36250467.
• Microfluidic immuno-serology assay revealed a limited diversity of protection against COVID-19 in patients with altered immunity.Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan JM, Buitrago-Pocasangre NC, Lele N, Asashima H, Racke MK, Wilson JE, Givens TS, Tomayko MM, Schulz WL, Longbrake EE, Hafler DA, Halene S, Fan R. bioRxiv. 2022 Sep 2; 2022 Sep 2. PMID: 36093346.
• Curriculum Innovations: Virtual Didactics as a Tool for Harmonizing Education About Rare Topics in Neuroimmunology.Peters J, Cohen JA, Corboy JR, Hopkins SE, Hua LH, Kakara M, McFaul D, Obeidat AZ, Yadav V, Longbrake EE. Neurol Educ. 2022 Sep. PMID: 38725979.
• Myelin Oligodendrocyte Glycoprotein-Associated Disorders.Longbrake E. Continuum (Minneap Minn). 2022 Aug 1. PMID: 35938661.
• The White Matter Rounds experience: The importance of a multidisciplinary network to accelerate the diagnostic process for adult patients with rare white matter disorders.Huang YT, Giacomini PS, Massie R, Venkateswaran S, Trudelle AM, Fadda G, Sharifian-Dorche M, Boudjani H, Poliquin-Lasnier L, Airas L, Saveriano AW, Ziller MG, Miller E, Martinez-Rios C, Wilson N, Davila J, Rush C, Longbrake EE, Longoni G, Macaron G, Bernard G, Tampieri D, Antel J, Brais B, La Piana R. Front Neurol. 2022; 2022 Jul 25. PMID: 35959404.
• Seroconversion after COVID-19 vaccination for multiple sclerosis patients on high efficacy disease modifying medications.Levit E, Longbrake EE, Stoll SS. Mult Scler Relat Disord. 2022 Apr; 2022 Mar 3. PMID: 35276450.
• Worsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic.Levit E, Cohen I, Dahl M, Edwards K, Weinstock-Guttman B, Ishikawa T, Kavak K, Leavitt V, Nelson K, Onomichi K, Bar-Or A, Perrone C, Riley C, Venkatesh S, De Jager PL, Xia Z, Longbrake EE. Mult Scler Relat Disord. 2022 Feb; 2022 Jan 4. PMID: 35016114.
• Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data.Epstein S, Xia Z, Lee AJ, Dahl M, Edwards K, Levit E, Longbrake EE, Perrone C, Kavak K, Weinstock-Guttman B, Diallo F, Ricci A, Riley CS, De Jager PL, Farber R, Wesley SF. Mult Scler Relat Disord. 2022 Jan; 2021 Dec 2. PMID: 34923427.
• A New England COVID-19 Registry of Patients With CNS Demyelinating Disease: A Pilot Analysis.Money KM, Mahatoo A, Samaan S, Anand P, Baber U, Bailey M, Bakshi R, Bouley A, Bower A, Cahill J, Houtchens M, Katz J, Lathi E, Levit E, Longbrake EE, McAdams M, Napoli S, Raibagkar P, Wade P, Sloane JA. Neurol Neuroimmunol Neuroinflamm. 2021 Sep; 2021 Aug 2. PMID: 34341094.
• (23)Na imaging: Worth its salt for understanding multiple sclerosis.Longbrake EE, Hafler DA. Proc Natl Acad Sci U S A. 2021 Aug 17. PMID: 34376559.
• Neuroinflammation Associated With Tumor Necrosis Factor-α Inhibitor Exposure.Yu AW, Pecsok M, Longbrake EE, Wesley SF. Neurol Clin Pract. 2021 Aug. PMID: 34484946.
• Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology.Hua LH, Obeidat AZ, Amezcua L, Cohen JA, Costello K, Dunn J, Gelfand JM, Goldman MD, Hopkins S, Jeffery D, Krieger S, Newsome SD, Shah S, Sicotte NL, Yadav V, Longbrake EE. Neurol Clin Pract. 2021 Aug. PMID: 34484933.
• Influence of immunomodulatory drugs on the gut microbiota.Cohen I, Ruff WE, Longbrake EE. Transl Res. 2021 Jul; 2021 Jan 27. PMID: 33515779.
• MOG-associated encephalitis following SARS-COV-2 infection.Peters J, Alhasan S, Vogels CBF, Grubaugh ND, Farhadian S, Longbrake EE. Mult Scler Relat Disord. 2021 May; 2021 Feb 23. PMID: 33647592.
• Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.Longbrake EE, Mao-Draayer Y, Cascione M, Zielinski T, Bame E, Brassat D, Chen C, Kapadia S, Mendoza JP, Miller C, Parks B, Xing D, Robertson D. Mult Scler. 2021 May; 2020 Jul 27. PMID: 32716690.
• The Role of Immune Checkpoint Therapy in Propagating Neurologic Immune-Related Adverse Events: Inducing or "Unmasking" Autoimmunity?Gardin T, Longbrake EE. Neurology. 2021 Apr 20; 2021 Mar 16. PMID: 33727404.
• Manifestations and impact of the COVID-19 pandemic in neuroinflammatory diseases.Levin SN, Venkatesh S, Nelson KE, Li Y, Aguerre I, Zhu W, Masown K, Rimmer KT, Diaconu CI, Onomichi KB, Leavitt VM, Levine LL, Strauss-Farber R, Vargas WS, Banwell B, Bar-Or A, Berger JR, Goodman AD, Longbrake EE, Oh J, Weinstock-Guttman B, Thakur KT, Edwards KR, Riley CS, Xia Z, De Jager PL. Ann Clin Transl Neurol. 2021 Apr; 2021 Feb 22. PMID: 33616290.
• Therapeutic considerations in a case of progressive encephalomyelitis with rigidity and myoclonus.Gluck L, Hernandez AL, Wesley SF, Fulbright RK, Longbrake EE, Stathopoulos P. J Neurol Sci. 2020 Sep 15; 2020 Jun 18. PMID: 32593886.
• Outcomes and future directions for neuroimmunology/multiple sclerosis fellowship training: Survey of recent trainees.Hua LH, Obeidat AZ, Longbrake EE. Mult Scler Relat Disord. 2020 Sep; 2020 Jun 10. PMID: 32585616.
• Sex effects across the lifespan in women with multiple sclerosis.Krysko KM, Graves JS, Dobson R, Altintas A, Amato MP, Bernard J, Bonavita S, Bove R, Cavalla P, Clerico M, Corona T, Doshi A, Fragoso Y, Jacobs D, Jokubaitis V, Landi D, Llamosa G, Longbrake EE, Maillart E, Marta M, Midaglia L, Shah S, Tintore M, van der Walt A, Voskuhl R, Wang Y, Zabad RK, Zeydan B, Houtchens M, Hellwig K. Ther Adv Neurol Disord. 2020; 2020 Jul 1. PMID: 32655689.
• Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United States.Obeidat AZ, Jassam YN, Hua LH, Cutter G, Ford CC, Halper J, Lisak RP, Sicotte NL, Longbrake EE. Neurology. 2020 Mar 17; 2020 Feb 27. PMID: 32107321.
• CXCR3+ T cells in multiple sclerosis correlate with reduced diversity of the gut microbiome.Choileáin SN, Kleinewietfeld M, Raddassi K, Hafler DA, Ruff WE, Longbrake EE. J Transl Autoimmun. 2020; 2019 Dec 20. PMID: 32743517.
• Siponimod Chips Away at Progressive MS.Longbrake EE, Hafler DA. Cell. 2019 Dec 12; 2019 Dec 12. PMID: 31951523.
• Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS.Baldassari LE, Salter AR, Longbrake EE, Cross AH, Naismith RT. Mult Scler. 2018 Sep; 2017 Aug 2. PMID: 28766993.
• Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count.Longbrake EE, Cantoni C, Chahin S, Cignarella F, Cross AH, Piccio L. Mult Scler. 2018 May; 2017 May 8. PMID: 28480794.
• Effectiveness of alternative dose fingolimod for multiple sclerosis.Longbrake EE, Kantor D, Pawate S, Bradshaw MJ, von Geldern G, Chahin S, Cross AH, Parks BJ, Rice M, Khoury SJ, Yamout B, Zeineddine M, Russell-Giller S, Caminero-Rodriguez A, Edwards K, Lathi E, VanderKodde D, Meador W, Berkovich R, Ge L, Bacon TE, Kister I. Neurol Clin Pract. 2018 Apr. PMID: 29708225.
• A Neurology Clerkship Curriculum Using Video-Based Lectures and Just-in-Time Teaching (JiTT).Dominguez M, DiCapua D, Leydon G, Loomis C, Longbrake EE, Schaefer SM, Becker KP, Detyniecki K, Gottschalk C, Salardini A, Encandela JA, Moeller JJ. MedEdPORTAL. 2018 Mar 16; 2018 Mar 16. PMID: 30800891.
• Quantitative visual tests after poorly recovered optic neuritis due to multiple sclerosis.Longbrake EE, Lancia S, Tutlam N, Trinkaus K, Naismith RT. Mult Scler Relat Disord. 2016 Nov; 2016 Nov 4. PMID: 27919490.
• The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.Solomon AJ, Bourdette DN, Cross AH, Applebee A, Skidd PM, Howard DB, Spain RI, Cameron MH, Kim E, Mass MK, Yadav V, Whitham RH, Longbrake EE, Naismith RT, Wu GF, Parks BJ, Wingerchuk DM, Rabin BL, Toledano M, Tobin WO, Kantarci OH, Carter JL, Keegan BM, Weinshenker BG. Neurology. 2016 Sep 27; 2016 Aug 31. PMID: 27581217.
• Linking Genotype to Clinical Phenotype in Multiple Sclerosis: In Search of the Holy Grail.Longbrake EE, Hafler DA. JAMA Neurol. 2016 Jul 1. PMID: 27244583.
• An older dog with newer tricks: Predicting efficacy of IFN-β treatment for multiple sclerosis.Wu GF, Longbrake EE. Neurol Neuroimmunol Neuroinflamm. 2016 Apr; 2016 Apr 7. PMID: 27110589.
• Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity.Longbrake EE, Cross AH. JAMA Neurol. 2016 Feb. PMID: 26720195.
• Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice.Longbrake EE, Cross AH, Salter A. Mult Scler J Exp Transl Clin. 2016 Jan-Dec; 2016 Nov 1. PMID: 28280599.
• Dimethyl fumarate associated lymphopenia in clinical practice.Longbrake EE, Cross AH. Mult Scler. 2015 May; 2014 Nov 28. PMID: 25432948.
• Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance.Longbrake EE, Naismith RT, Parks BJ, Wu GF, Cross AH. Mult Scler J Exp Transl Clin. 2015 Jan-Dec; 2015 Jul 31. PMID: 26550483.